Early tirofiban versus heparin for bridging dual antiplatelet therapy in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting: a multicenter randomized controlled trial protocol (the THACE-CABG trial)

MLA

Liang Chen, et al. “Early Tirofiban versus Heparin for Bridging Dual Antiplatelet Therapy in Patients Undergoing Coronary Endarterectomy Combined with Coronary Artery Bypass Grafting: A Multicenter Randomized Controlled Trial Protocol (the THACE-CABG Trial).” Trials, vol. 25, no. 1, Jan. 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s13063-023-07737-8.

APA

Liang Chen, Ming-Xin Gao, Xin Du, Chi Wang, Wen-Yuan Yu, Hong-Li Liu, Xiao-Hang Ding, Bo-Lin Wang, Kui Zhang, Dong Xu, Zhen Han, Bao-Dong Xie, Ran Dong, & Yang Yu. (2024). Early tirofiban versus heparin for bridging dual antiplatelet therapy in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting: a multicenter randomized controlled trial protocol (the THACE-CABG trial). Trials, 25(1), 1–14. https://doi.org/10.1186/s13063-023-07737-8

Chicago

Liang Chen, Ming-Xin Gao, Xin Du, Chi Wang, Wen-Yuan Yu, Hong-Li Liu, Xiao-Hang Ding, et al. 2024. “Early Tirofiban versus Heparin for Bridging Dual Antiplatelet Therapy in Patients Undergoing Coronary Endarterectomy Combined with Coronary Artery Bypass Grafting: A Multicenter Randomized Controlled Trial Protocol (the THACE-CABG Trial).” Trials 25 (1): 1–14. doi:10.1186/s13063-023-07737-8.